Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020;29(11):1935-1955.
doi: 10.1007/s00044-020-02625-1. Epub 2020 Sep 10.

What are the drugs having potential against COVID-19?

Kaan Kucukoglu  1 , Nagihan Faydalı  1 , Dilek Bul  1
Affiliations
Review

What are the drugs having potential against COVID-19?

Kaan Kucukoglu et al. Med Chem Res. 2020.

Abstract

A disease emerged in the city of Wuhan, Hubei Province, Central China in the last month of 2019. It was pneumonia caused by a newly emerged coronavirus called COVID-19, later. Coronaviruses are enveloped RNA viruses belong to the Betacoronavirus family and infected birds, humans, and other mammals. In March 2020, the World Health Organization declared the COVID-19 outbreak could be characterized as a global pandemic because the disease spread, and a large number of people were infected and died in many countries on different continents by virtue of this new virus. Now, intensive work is underway about the pathogenic mechanisms and epidemiological properties of COVID-19, and a great effort is made to develop effective specific therapeutic drugs, vaccines, and/or treatment strategies against these diseases. Herein, we have focused on all treatment options available against COVID-19 pneumonia in this text.

Keywords: Antiviral; COVID-19; Cellular therapy; Drug; Immunotherapy; Pandemic.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestThe authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Molecular structure of tocilizumab. Right panel, schematic representation of the two-dimensional structure. Left panel, three-dimensional structural molecular model. (Produced by Drs. Ohta and Kobayashi, Chugai Pharmaceutical Co., Ltd.) (Ohsugi 2020)
Fig. 2
Fig. 2
Structure of humanized bevacizumab antibody
Fig. 3
Fig. 3
Chemical formula of cyclosporine A
Fig. 4
Fig. 4
Chemical Structures of antiviral drugs
Fig. 5
Fig. 5
Chemical formulas of neuraminidase inhibitors
Fig. 6
Fig. 6
Chemical Structures of antimalarial drugs
Fig. 7
Fig. 7
Chemical Structures of some other drugs
Fig. 8
Fig. 8
Chemical structures of Chinese medicine
See this image and copyright information in PMC

References

    1. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke MO, Baric RS, Denison MR. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9:e00221–e002218. - PMC - PubMed
    1. Al-Tawfiq JA, Memish ZA. Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Expert Rev Anti Infect Ther. 2017;15:269–275. - PMC - PubMed
    1. Anti-2019-nCoV Volunteers, Li Z, Wu M, Yao J, Guo J, Liao X, Song S, Li J, Duan G, Zhou Y, Wu X, Zhou Z, Wang T, Hu M, Chen X, Fu Y, Lei C, Dong H, Xu C, Hu Y, Han M, Zhou Y, Jia H, Chen X, Yan J (2020) Caution on kidney dysfunctions of COVID-19 patients. medRxiv. 10.1101/2020.02.08.20021212
    1. Arabi Y, Balkhy H, Hajeer AH, Bouchama A, Hayden FG, Al-Omari A, Al-Hameed FM, Taha Y, Shindo N, Whitehead J, Merson L, AlJohani S, Al-Khairy K, Carson G, Luke TC, Hensley L, Al-Dawood A, Al-Qahtani S, Modjarrad K, Sadat M, Rohde G, Leport C, Fowler R. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus. 2015;4:709. - PMC - PubMed
    1. Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, Kojan S, Al Jeraisy M, Deeb AM, Assiri AM, Al-Hameed F, AlSaedi A, Mandourah Y, Almekhlafi GA, Sherbeeni NM, Elzein FE, Memon J, Taha Y, Almotairi A, Maghrabi KA, Qushmaq I, Al Bshabshe A, Kharaba A, Shalhoub S, Jose J, Fowler RA, Hayden FG, Hussein MA, The MIRACLE trial group Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018;19:81. - PMC - PubMed

LinkOut - more resources